Landos Biopharma, Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|
| Revenue | — | — | $18.0M | $0 |
| Operating income | −$22.7M | −$40.6M | −$38.8M | −$30.7M |
| Net income | −$21.9M | −$39.3M | −$38.4M | −$30.1M |
| Total assets | $38.0M | $45.3M | $92.9M | $30.3M |
| Total liabilities | $6.2M | $6.1M | $16.6M | $11.3M |
| Equity | $31.8M | $39.1M | $76.3M | −$54.0M |
| EPS (diluted) | $-3.50 | $-9.76 | $-1.02 | — |
| Shares out. | 31.2M | 40.3M | 40.3M | 12.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2023- Operating margin
- —
- Net margin
- —
- Return on equity
- −69.0%
- Return on assets
- −57.7%
- Return on capital (ROCE)
- −71.5%
- Liabilities / assets
- 16.4%
- Debt / equity
- 0.20×
- Book value / share
- $1.02
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2023- Altman Z″ (distress)
- -6.51distress
- Accruals / assets
- −3.8%clean
- Piotroski F-Score
- 3/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Other material eventMay 23, 2024
- Shareholder voteMay 23, 2024
- Entered a material agreement · Regulation FD disclosureMar 25, 2024
- Results of operationsMar 21, 2024
- Regulation FD disclosureJan 4, 2024
- Regulation FD disclosureNov 21, 2023
- Results of operationsNov 9, 2023
- Director / officer changeSep 21, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.